Popular Stories

Biotechnology

CytoKinetics – On the Threshold of some big Catalysts!

CytoKinetics, Inc. (NASDAQ: CYTK), a late-stage biopharmaceutical company, is developing therapeutics for the treatment of cardiovascular and neuromuscular diseases that are characterized by impaired muscle function such as amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA) heart failure and hypertrophic cardiomyopathies (HCM). The Company announced preclinical...

Rigel Pharmaceuticals has Multiple Aces Up its Sleeves!

Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) is focused on developing innovative small molecule drugs that target hematologic disorders, cancer and rare immune diseases. The Company announced positive topline results from a phase 2 evaluation of fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, intended for the...

5 Biotech Companies That Should Be on Your Investment Watchlist!

Biotech Companies continue to show resurgence even in these challenging times, with more and more companies persevering with bringing their clinical candidates to fruition. While Vaccine development and therapeutics to combat the COVID-19 pandemic are at the forefront of development activities in the biotech sector,...

5 Biotech Companies with Upcoming Catalysts

Biotech Companies continue to show resurgence even in these challenging times, with more and more companies persevering with bringing their clinical candidates to fruition. While Vaccine development and therapeutics to combat the COVID-19 pandemic are at the forefront of development activities in the biotech sector,...

Can Know Lab Deliver on the Promise of its “Disruptive Technology”?

Know Labs, Inc. (OTCQB: KNWN) formerly known as Visualant, is a premier non-invasive medical diagnostics company that is leveraging its proprietary electromagnetic energy technology platforms, namely ChromaID and Bio-RFID technologies, to capture the unique molecular signature of any substance or material. The Company shared preliminary study...

6 Reasons Why Replimune Offers Huge Growth Potential!

Replimune group, Inc. (NASDAQ: REPL) is leveraging the power of its proprietary Immulytic platform to create a leading-edge oncolytic immunotherapy program that can generate a patient-specific local as well as systemic immune response. The therapies not only fight against the current cancer but also eliminate...

Infinity Pharmaceuticals: Can Eganelisib prove to be a gamechanger in Immuno-Oncology?

Infinity Pharmaceuticals (NASDAQ: INFI) novel approach is based on Targeting Immune Suppressive Macrophages by selectively inhibiting PI3K-Gamma. The Company’s lead candidate eganelisib, is a first-in-class, oral, once-daily selective inhibitor of phosphoinositide-3-kinase gamma (PI3K-gamma), that has the potential to transform the immuno-oncology space. IPI-549 has demonstrated...

WordPress Video Lightbox Plugin